Arvinas Projects Cash Runway Through Mid-2028 Amid Upcoming Clinical Readouts
Arvinas (ARVN) has provided updated financial and clinical guidance, stating that its current cash reserves are expected to sustain operations into the second half of 2028. The company is focusing on strategic capital allocation, prioritizing investments in programs backed by emerging evidence to maximize long-term value creation. The biotechnology firm's roadmap includes multiple Phase I clinical data readouts scheduled through 2027. CEO Randy Teel emphasized a data-driven approach to development, ensuring that resources are directed toward the most promising therapeutic candidates within their pipeline.